CXI Healthcare Technology Group Decides on Third-Party Rights Offering Raising 48 Billion Won, Dilution of 240% of Outstanding Shares
CXI Healthcare Technology Group Limited resolved on July 21, 2026 to conduct a third-party rights offering to raise 48 billion won in operating funds.
The offering consists of 8,000,000 new shares at an issue price of 6,000 won per share, representing a 14.63% premium over the reference price adjusted for a 5:1 reverse stock split. Post-split outstanding shares are 3,333,932, making this issuance a massive dilution of approximately 240% of existing shares.
Funds will be allocated to three individual investors including the largest shareholder LIN JINSHENG, with a 1-year lock-up restriction on resale to mitigate immediate selling pressure.
The plan is conditional on shareholder approval of a charter amendment at an extraordinary general meeting scheduled for August 11, 2026; failure to approve may lead to cancellation or modification. The company cited its foreign holding company structure and difficulties in raising funds in the Korean market as justification for the third-party allotment.
Proceeds are earmarked for tea plantation operations, AI and digital system development, personnel costs, and marketing expenses. While the company argues this strengthens its going-concern base and long-term value, the immediate dilution impact on existing shareholders is severe.
[AI Summary]CXI's decision to issue shares equivalent to 240% of its current outstanding stock imposes substantial short-term dilution risk on shareholders. The funds are allocated to operational needs rather than high-growth investments, and the counterparties are individual investors without strong institutional backing, raising governance concerns. The outcome hinges on shareholder vote.
KOSDAQ Filing Information
Report On Major Matters (Decision On Paid-In Capital Increase)
Company: CXI Healthcare Technology Group (900120)
Submission: CXI Healthcare Technology Group Limited